MX2022002823A - Composiciones inmunoterapeuticas. - Google Patents
Composiciones inmunoterapeuticas.Info
- Publication number
- MX2022002823A MX2022002823A MX2022002823A MX2022002823A MX2022002823A MX 2022002823 A MX2022002823 A MX 2022002823A MX 2022002823 A MX2022002823 A MX 2022002823A MX 2022002823 A MX2022002823 A MX 2022002823A MX 2022002823 A MX2022002823 A MX 2022002823A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapeutic compositions
- virus
- vlps
- gbm
- mlv
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 2
- 241000714177 Murine leukemia virus Species 0.000 abstract 2
- 208000005017 glioblastoma Diseases 0.000 abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 abstract 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 1
- 229930182490 saponin Natural products 0.000 abstract 1
- 150000007949 saponins Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897603P | 2019-09-09 | 2019-09-09 | |
| PCT/EP2020/075002 WO2021048081A1 (en) | 2019-09-09 | 2020-09-08 | Immunotherapeutic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002823A true MX2022002823A (es) | 2022-10-21 |
Family
ID=72603444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002823A MX2022002823A (es) | 2019-09-09 | 2020-09-08 | Composiciones inmunoterapeuticas. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20210069321A1 (enExample) |
| EP (1) | EP4028051A1 (enExample) |
| JP (1) | JP2022547298A (enExample) |
| CN (1) | CN114466659A (enExample) |
| BR (1) | BR112022004228A2 (enExample) |
| CA (1) | CA3092525A1 (enExample) |
| IL (1) | IL290854A (enExample) |
| MX (1) | MX2022002823A (enExample) |
| WO (1) | WO2021048081A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025104A2 (pt) | 2017-05-30 | 2020-06-23 | Glaxosmithkline Biologicals S.A. | Método de fabricar um sistema de entrega não viral, sistema de entrega não viral, e, composição |
| EP3886901A1 (en) * | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| KR20220038608A (ko) * | 2019-05-31 | 2022-03-29 | 배리에이션 바이오테크놀로지스 아이엔씨. | 다형성 교모세포종의 치료를 위한 면역치료 조성물 |
| WO2021038508A1 (en) | 2019-08-30 | 2021-03-04 | Glaxosmithkline Biologicals Sa | Jet mixing lipid nanoparticle manufacturing process |
| WO2023020994A1 (en) * | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| US20260224692A1 (en) * | 2023-01-26 | 2026-08-06 | The General Hospital Corporation | T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus |
| WO2025179112A1 (en) * | 2024-02-23 | 2025-08-28 | Curevo, Inc. | Immunogenic compositions for the prevention of herpes zoster |
| WO2025180443A1 (en) * | 2024-02-29 | 2025-09-04 | Immunadd Inc. | Adjuvant composition, pharmaceutical composition comprising the same, and method for preventing or treating disease caused by viral infection, bacterial infection, protozoal infection or cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| CA2252972C (en) | 1998-11-26 | 2012-09-18 | National Research Council Of Canada | Serum-free production of recombinant proteins and adenoviral vectors |
| US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| PT1284740E (pt) | 2000-05-19 | 2008-07-09 | Corixa Corp | Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| US7288640B2 (en) | 2002-07-08 | 2007-10-30 | Corixa Corporation | Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| CN103550764A (zh) * | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| CA2728739C (en) * | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| SG190937A1 (en) | 2010-12-14 | 2013-07-31 | Glaxosmithkline Biolog Sa | Mycobacterium antigenic composition |
| JP6232544B2 (ja) * | 2011-11-11 | 2017-11-22 | ヴァリエーション バイオテクノロジーズ インコーポレイテッド | サイトメガロウイルスの治療のための組成物及び方法 |
| CN110088227B (zh) | 2016-12-23 | 2023-01-10 | 库斯图姆多特公司 | 具有iii-v族核心和合金化ii-vi族外壳的量子点 |
-
2020
- 2020-09-08 CN CN202080062933.7A patent/CN114466659A/zh active Pending
- 2020-09-08 MX MX2022002823A patent/MX2022002823A/es unknown
- 2020-09-08 JP JP2022515475A patent/JP2022547298A/ja active Pending
- 2020-09-08 EP EP20775584.4A patent/EP4028051A1/en not_active Withdrawn
- 2020-09-08 BR BR112022004228A patent/BR112022004228A2/pt not_active IP Right Cessation
- 2020-09-08 US US17/014,028 patent/US20210069321A1/en not_active Abandoned
- 2020-09-08 WO PCT/EP2020/075002 patent/WO2021048081A1/en not_active Ceased
- 2020-09-08 CA CA3092525A patent/CA3092525A1/en active Pending
-
2022
- 2022-02-23 IL IL290854A patent/IL290854A/en unknown
- 2022-09-08 US US17/940,117 patent/US20230022956A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN114466659A (zh) | 2022-05-10 |
| IL290854A (en) | 2022-04-01 |
| EP4028051A1 (en) | 2022-07-20 |
| US20230022956A1 (en) | 2023-01-26 |
| US20210069321A1 (en) | 2021-03-11 |
| WO2021048081A1 (en) | 2021-03-18 |
| CA3092525A1 (en) | 2021-03-09 |
| JP2022547298A (ja) | 2022-11-11 |
| BR112022004228A2 (pt) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004228A2 (pt) | Composições imunoterapêuticas | |
| WO2022221335A8 (en) | Respiratory virus combination vaccines | |
| AU2019293244A8 (en) | Personalized cancer vaccine epitope selection | |
| EP4344706A3 (en) | Methods for treating or preventing asthma by administering an il-4r antagonist | |
| EP4374707A3 (en) | Coffee replicas produced from individual components | |
| EP4004036A4 (en) | VIRUS-LIKE PARTICLE VACCINES | |
| PH12019501366A1 (en) | Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them | |
| UA118651C2 (uk) | Рекомбінантний вектор hvt, який експресує антигени патогенів птахів, та композиція, що його містить | |
| WO2018161049A8 (en) | Compositions and methods for inducing hiv-1 antibodies | |
| GB2434367A (en) | Improved vaccines | |
| NZ741875A (en) | Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof | |
| MX353189B (es) | Composiciones y su uso en el tratamiento de citomegalovirus. | |
| WO2017152146A3 (en) | Compositions and methods for inducing hiv-1 antibodies | |
| EP3784990A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING TUMOR-RELATED ANTIBODIES AND ANTIGENS | |
| MX2021009105A (es) | Toxinas apxia, apxiia y apxiiia inactivadas. | |
| EP3858873A4 (en) | Fluororesin, fluororesin particles, and methods for producing these | |
| EP3804748A4 (en) | Phosphorylated polypeptide antigen vaccine, preparation method therefor and application thereof | |
| EP3722311A4 (en) | HUMAN ANTI-IL6 MONOCLONAL ANTIBODIES, METHOD FOR THE PREPARATION AND USE THEREOF | |
| PH12017501795B1 (en) | Pestivirus vaccines for congenital tremors | |
| MX2025003959A (es) | Materiales y metodos para expresion sin celulas de concatemeros de epitopos de vacuna | |
| SG11201900491PA (en) | Cement composition, method for producing same, and method for producing fly ash for cement composition | |
| SG11202106494RA (en) | Compositions, methods and uses for eliciting an immune response | |
| EP3777816A4 (en) | POLYMERIZABLE COMPOSITION FOR DENTAL MATERIAL AND DENTAL MATERIAL OBTAINED FROM THIS COMPOSITION | |
| BR112021024157A2 (pt) | Composições imunoterapêuticas para tratamento de glioblastoma multiforme | |
| EP3991747A4 (en) | Preparations containing anti-lag-3 antibody, and preparation method therefor and use thereof |